Inmune Bio, INC

INmune Bio announced the receipt of approximately $4.6 million in research and development cash rebates from Australia and the United Kingdom, strengthening its financial position and extending its cash runway.

INmune Bio Inc. has entered into agreements to extend the maturity date of certain outstanding warrants and secure cash through their partial exercise at a reduced price.

INmune Bio Inc. shareholders approved an increase in the number of shares available under the 2021 Stock Incentive Plan and implemented an evergreen provision.

INmune Bio announced statistically significant results from exploratory MRI imaging analyses in its Phase 2 MINDFuL trial of XPro for early Alzheimer's disease, showing a treatment effect on white matter.

INmune Bio announced its lead drug candidate, XPro (pegipanermin), has received FDA Fast Track designation for the treatment of early Alzheimer's disease.

INmune Bio Inc. and Anthony Nolan have entered into an amended and restated Material Transfer and License Agreement to secure long-term supply of umbilical cord tissue for INmune Bio's CORDStrom platform.

INmune Bio reported a significant net loss and going concern doubt, driven by a failed Alzheimer's trial and a substantial asset impairment, despite progress in other programs and recent capital raises.

INmune Bio Inc. reported a widened net loss for Q2 2025, primarily due to a $16.5 million impairment charge related to its Alzheimer's drug candidate, XPro, following mixed Phase 2 results, alongside a CEO transition and ongoing liquidity concerns.

INmune Bio Inc. reports a net loss of $9.7 million for Q1 2025 and is advancing its CORDStrom product towards a BLA submission while facing going concern uncertainties.

INmune Bio's Q3 2024 report reveals continued losses and a need for additional funding to sustain operations.

INmune Bio's Q2 2024 report reveals a significant increase in net losses and operating expenses, primarily driven by escalating research and development costs for its clinical programs.

INmune Bio's first quarter 2024 results show a net loss of $11.0 million and increased research and development expenses, raising concerns about the company's ability to continue as a going concern.

INmune Bio's 2024 annual report highlights progress in clinical trials, particularly for CORDStrom in RDEB, while acknowledging ongoing financial challenges and efforts to secure additional funding.

INmune Bio Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

INmune Bio Inc. released its 10-K annual report, detailing its financial status and advancements in its immunotherapy programs targeting cancer, Alzheimer's disease, and treatment-resistant depression.

Inmune Bio Director Scott Juda exercised 14,801 warrants and secured an extension on the remaining warrants through a new agreement.

Inmune Bio's Chief Scientific Officer, Mark William Lowdell, exercised warrants for 7,211 shares of common stock and secured an extension on remaining warrants.

Inmune Bio CEO David J. Moss exercised 9,014 common stock purchase warrants and secured an extension for the remaining warrants.

Inmune Bio's Chief Scientific Officer, Mark William Lowdell, was granted 600,000 stock options with an exercise price of $1.48.

Inmune Bio, Inc. CEO David J. Moss received a grant of 750,000 stock options with a $1.48 exercise price, vesting over four years.

Inmune Bio's CFO, Cory Randall Ellspermann, was granted 300,000 stock options with an exercise price of $1.48, vesting over four years.

INmune Bio Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditors, and approve an updated stock incentive plan.

INmune Bio Inc. is seeking stockholder approval to reprice certain outstanding stock options for current directors, executive officers, and employees to address retention and competitiveness concerns.

INmune Bio Inc. has dismissed Marcum LLP and appointed CBIZ CPAs as their new independent registered public accounting firm, leading to an amendment of the proxy statement and a rescheduling of the annual meeting.

INmune Bio Inc. files a supplement to its proxy statement to correct a typographical error concerning the voting standard for the approval of the Second Amended and Restated 2021 Stock Incentive Plan.

INmune Bio Inc. will hold its annual stockholder meeting virtually on May 28, 2025, to vote on the election of directors, ratification of the accounting firm, executive compensation, and approval of the Second Amended and Restated 2021 Stock Incentive Plan.

INmune Bio Inc. will hold its annual stockholders meeting virtually on July 19, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Highbridge Capital Management, LLC reported a 5.2% beneficial ownership stake in Inmune Bio, Inc., primarily through warrants.

CVI Investments, Inc. and Heights Capital Management, Inc. disclose a 4.9% passive beneficial ownership in INmune Bio Inc. common stock, primarily through warrants.

Multiple investment entities and individuals, including Praetorian Capital and Mongolia Growth Group, have disclosed their beneficial ownership in Inmune Bio, Inc., totaling up to 3.4% of outstanding shares.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have disclosed a combined beneficial ownership of 5.5% of INmune Bio Inc.'s common stock.

Praetorian Capital Fund LLC, Mongolia (Barbados) Corp., and related entities, including Harris Kupperman, have disclosed a combined beneficial ownership of 7.2% in Inmune Bio, Inc. as of March 31, 2025.

Harris Kupperman, through various affiliated entities including Praetorian Capital and Mongolia Growth Group, has disclosed a combined passive beneficial ownership of 5.5% in INmune Bio Inc., totaling 1,238,963 shares.